Bone marrow transplantation for beta-thalassemia.

Area of Science:

• Hematology
• Transplantation Medicine
• Pediatric Oncology

Background:

• Thalassemia is a serious inherited blood disorder.
• Bone marrow transplantation (BMT) is the only radical cure for thalassemia.
• Risk stratification is crucial for predicting BMT outcomes.

Purpose of the Study:

• To evaluate the efficacy of bone marrow transplantation in thalassemia patients.
• To assess survival and event-free survival rates based on risk stratification in pediatric patients.
• To analyze outcomes in adult thalassemic patients undergoing BMT.

Main Methods:

• Patients younger than 17 years were classified into three risk groups based on clinical factors (portal fibrosis, hepatomegaly, chelation history).
• Adult patients (older than 16 years) were analyzed separately.
• Survival and event-free survival rates were calculated for each group.

Main Results:

• Class 1 pediatric patients showed 93% survival and 91% event-free survival.
• Class 2 pediatric patients had 87% survival and 83% event-free survival.
• Class 3 pediatric patients demonstrated 79% survival and 58% event-free survival.
• Adult patients achieved 66% survival and 62% event-free survival.

Conclusions:

• Bone marrow transplantation is a highly effective curative treatment for thalassemia.
• Risk stratification accurately predicts outcomes in pediatric BMT recipients.
• Outcomes for adult thalassemic patients are less favorable than for pediatric patients.